Positive airway pressure (PAP) therapy in heart patients with sleep apnoea can reduce mortality rates by up to 38%, analysis from ResMed (ASX:RMD) suggests.

Seasoned medical device executive Michael Dale will take over from Stuart A Randle as CEO of GI Dynamics (ASX:GID) from next month. [ + ]

The experimental drug ZMapp has proven effective in treating the Ebola virus in monkeys. [ + ]

Biotechnology company OncoSynergy has launched a crowdfunding campaign to enable studies of an experimental cancer drug in Ebola infection. It is hoped that the drug may be able to combat the Ebola crisis in west Africa, which has already claimed almost 1500 lives. [ + ]

AMS Instrumentation & Calibration has been appointed the exclusive distributor for the optek range of analytical instrumentation in its territories. [ + ]

Deciphering how to extract quantities of endothelial stem cells from the placenta is providing a potential new use for an organ usually discarded. [ + ]

Phylogica (ASX:PYC) has added a Japanese patent and two more from the US to its intellectual property portfolio.

A synthetic ceramic that is tough, highly porous and bioactive is being used to engineer bone. [ + ]

Analytical solutions provider AXT has signed an agreement with the Nano-scale Materials Analysis product lines of Thermo Fisher Scientific, whereby AXT will become the company's distributor in Australia and New Zealand for its Surface Analysis and Microanalysis product lines. [ + ]

AusBiotech fully supports the Australian Greens' moving of an amendment in the Senate to put in place quarterly payments for small and medium-size businesses eligible for an R&D Tax Incentive refund.

EOS Space Systems is collaborating with security and aerospace company Lockheed Martin to provide services to government and commercial customers in the space industry. The companies have entered into a strategic cooperation agreement for the development and rollout of space-tracking capabilities at a new facility in Western Australia. [ + ]

Mesoblast (ASX:MSB) has announced its financial results for FY14 and laid out a five-pronged strategy for commercialising its key regenerative medicine products.

Researchers have identified the specific portion of insulin that the immune system targets in type 1 diabetes, providing a potential pathway to improved treatments for the condition.

A US ITC judge has found in favour of ResMed (ASX:RMD) in the company's patent infringement action against China's BMC Medical, and has recommended an import ban.

Following on from a successful first-ever Tech Transfer Summit (TTS) Australia in 2013, the TTS Global Initiative and AusBiotech are pleased to confirm the Australian chapter will be returning to South Australia next week with the support of major partner BioSA.